Status: Recruiting
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Participants needed: 45
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kailin Yang, MD, PhDUpdated: Jun 17, 2026Locations: 1
Eligibility criteria
Subjects must have histologically or cytologically confirmed WHO grade 4 glioma... [+50]
Prior treatment toxicities not resolved to ≤ Grade 1 according to NCI CTCAE Vers... [+14]